Reimbursement Expansion To Fuel China Pharma Growth In 2011 (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - China's pharmaceutical market is expected to grow around 26% in the coming year with much of the growth fueled by continued implementation of the government's Essential Drug List (EDL) and reimbursement expansion via government insurance plans, said Katherine Lu, senior analyst for China healthcare at Oppenheimer & Co
You may also be interested in...
Are China's Rising Labor Costs Good For Big Pharma?
HONG KONG - Rising labor costs are putting stress on manufacturing operations in China, but may prove to be a boon in the long term for companies focused on the world's fastest-growing domestic market
Are China's Rising Labor Costs Good For Big Pharma?
HONG KONG - Rising labor costs are putting stress on manufacturing operations in China, but may prove to be a boon in the long term for companies focused on the world's fastest-growing domestic market
Is China A Black Swan For Big Pharma? (Part 2 of 2)
[Editor's note: This is part two of a two part story; part one appeared in PharmAsia News, April 25, 2010.]